Phase 3 Multicenter, Double-Blind, randomized, placebo-controlled trail of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

Investigator: Raj Satkunasivam, MD

Study Coordinator: Taliah Muhammad

Status: Enrolling Number: NCT04197986

Phone: 346.238.4523

Protocol Number: PRO00023986


This is a Phase 3, Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to evaluate the efficacy of Infigratinib in adult patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations (mutations, and gene fusions or translocations)who are within 120 days following nephrouretectomy,distal uretectomy, or cystectomy and ineligible for cisplatin-based (neo) adjuvant chemotherapy or with residual disease after neoadjuvant therapy. NCT: NCT04197986
More to Explore